292 related articles for article (PubMed ID: 34449248)
1. A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer.
Westaby D; Fenor de La Maza MLD; Paschalis A; Jimenez-Vacas JM; Welti J; de Bono J; Sharp A
Annu Rev Pharmacol Toxicol; 2022 Jan; 62():131-153. PubMed ID: 34449248
[TBL] [Abstract][Full Text] [Related]
2. New approaches to targeting the androgen receptor pathway in prostate cancer.
Velho PI; Bastos DA; Antonarakis ES
Clin Adv Hematol Oncol; 2021 Apr; 19(4):228-240. PubMed ID: 33989272
[TBL] [Abstract][Full Text] [Related]
3. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
[TBL] [Abstract][Full Text] [Related]
4. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.
Zhao J; Ning S; Lou W; Yang JC; Armstrong CM; Lombard AP; D'Abronzo LS; Evans CP; Gao AC; Liu C
Mol Cancer Ther; 2020 Aug; 19(8):1708-1718. PubMed ID: 32430485
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer.
Mitsiades N; Kaochar S
Endocr Relat Cancer; 2021 Jul; 28(8):T19-T38. PubMed ID: 34128827
[TBL] [Abstract][Full Text] [Related]
6. Second generation androgen receptor antagonists and challenges in prostate cancer treatment.
Chen Y; Zhou Q; Hankey W; Fang X; Yuan F
Cell Death Dis; 2022 Jul; 13(7):632. PubMed ID: 35864113
[TBL] [Abstract][Full Text] [Related]
7. Androgens in prostate cancer: A tale that never ends.
Hou Z; Huang S; Li Z
Cancer Lett; 2021 Sep; 516():1-12. PubMed ID: 34052327
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor antagonists for prostate cancer therapy.
Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
[TBL] [Abstract][Full Text] [Related]
9. Novel drugs targeting the androgen receptor pathway in prostate cancer.
Mateo J; Smith A; Ong M; de Bono JS
Cancer Metastasis Rev; 2014 Sep; 33(2-3):567-79. PubMed ID: 24390422
[TBL] [Abstract][Full Text] [Related]
10. New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway.
Attard G; Richards J; de Bono JS
Clin Cancer Res; 2011 Apr; 17(7):1649-57. PubMed ID: 21372223
[TBL] [Abstract][Full Text] [Related]
11. A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.
Auvin S; Öztürk H; Abaci YT; Mautino G; Meyer-Losic F; Jollivet F; Bashir T; de Thé H; Sahin U
Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31431473
[TBL] [Abstract][Full Text] [Related]
12. Targeting extra-gonadal androgens in castration-resistant prostate cancer.
Grist E; de Bono JS; Attard G
J Steroid Biochem Mol Biol; 2015 Jan; 145():157-63. PubMed ID: 25251387
[TBL] [Abstract][Full Text] [Related]
13. Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer.
Leo J; Dondossola E; Basham KJ; Wilson NR; Alhalabi O; Gao J; Kurnit KC; White MG; McQuade JL; Westin SN; Wellberg EA; Frigo DE
Endocrinology; 2023 Apr; 164(6):. PubMed ID: 37154098
[TBL] [Abstract][Full Text] [Related]
14. Targeting the androgen receptor and overcoming resistance in prostate cancer.
Einstein DJ; Arai S; Balk SP
Curr Opin Oncol; 2019 May; 31(3):175-182. PubMed ID: 30893145
[TBL] [Abstract][Full Text] [Related]
15. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
16. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
Isaacsson Velho P; Carducci MA
Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
[TBL] [Abstract][Full Text] [Related]
17. Hormonal Therapy for Prostate Cancer.
Desai K; McManus JM; Sharifi N
Endocr Rev; 2021 May; 42(3):354-373. PubMed ID: 33480983
[TBL] [Abstract][Full Text] [Related]
18. Androgen action and metabolism in prostate cancer.
Green SM; Mostaghel EA; Nelson PS
Mol Cell Endocrinol; 2012 Sep; 360(1-2):3-13. PubMed ID: 22453214
[TBL] [Abstract][Full Text] [Related]
19. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
[TBL] [Abstract][Full Text] [Related]
20. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
Lakshmana G; Baniahmad A
Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]